A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia

The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to...

Full description

Saved in:
Bibliographic Details
Published in:Health Affairs 2001-05, Vol.20 (3), p.104-114
Main Authors: Birkett, Donald J, Mitchell, Andrew S, McManus, Peter
Format: Article
Language:English
Subjects:
Australia
Committees
Cost analysis
Cost control
Cost Sharing
Cost-Benefit Analysis
Decision making
Drug Approval
Drug Costs
Drug dosages
Drug Industry - organization & administration
Evidence-Based Medicine
Financing, Government
Formularies as Topic
Government subsidies
Health Services Accessibility - organization & administration
Hospitals
Humans
Industrialized nations
Marketing
National Health Programs - organization & administration
Outcome Assessment (Health Care)
Patients
Pharmaceutical industry
Prescription drugs
Rate Setting and Review
Statistical analysis
Studies
Subsidies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03
cites cdi_FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03
container_end_page 114
container_issue 3
container_start_page 104
container_title Health Affairs
container_volume 20
creator Birkett, Donald J
Mitchell, Andrew S
McManus, Peter
description The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.
doi_str_mv 10.1377/hlthaff.20.3.104
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_71217685</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>71217685</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03</originalsourceid><addsrcrecordid>eNpdkM1r3DAUxEVpaTZJ7zkV0UMhB2_f04dlH802aQKBFpKehSxLawWvvZXshvz3VdklgRweA4_fDMMQcoGwRq7Ut36Ye-P9msGarxHEO7JCKUQhGVTvyQqYqgqmUJ6Q05QeAUqGUH8kJ4iykvlW5LqhmynNxZX3zs7hrxtdSrTZ7-NkbE8fJvo9Llt6v7QpdM-0GTv6KwYbxi29HWmzpDmaIZhz8sGbIblPRz0jv6-vHjY3xd3PH7eb5q6wgtVzIRg3rHW-rsGZ0rYcHdRVBZIbiR6wQ9u5urTghFJKVNBZ8BaZKD2XbQv8jHw95OZ-fxaXZr0LybphMKOblqQVMlRlJTP45Q34OC1xzN00A1EK4FhnCA6QjVNK0Xm9j2Fn4rNG0P8H1seBs0fz_BTZ8vmYu7Q7170ajotm4PIA9GHbP4XodNqZYcg4ajuNsxvnl7B_L6eExA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>204640319</pqid></control><display><type>article</type><title>A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia</title><source>International Bibliography of the Social Sciences (IBSS)</source><source>ABI/INFORM Collection</source><source>Politics Collection</source><source>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</source><source>PAIS Index</source><creator>Birkett, Donald J ; Mitchell, Andrew S ; McManus, Peter</creator><creatorcontrib>Birkett, Donald J ; Mitchell, Andrew S ; McManus, Peter</creatorcontrib><description>The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.</description><identifier>ISSN: 0278-2715</identifier><identifier>EISSN: 1544-5208</identifier><identifier>EISSN: 2694-233X</identifier><identifier>DOI: 10.1377/hlthaff.20.3.104</identifier><identifier>PMID: 11585158</identifier><language>eng</language><publisher>United States: Health Affairs</publisher><subject>Australia ; Committees ; Cost analysis ; Cost control ; Cost Sharing ; Cost-Benefit Analysis ; Decision making ; Drug Approval ; Drug Costs ; Drug dosages ; Drug Industry - organization &amp; administration ; Evidence-Based Medicine ; Financing, Government ; Formularies as Topic ; Government subsidies ; Health Services Accessibility - organization &amp; administration ; Hospitals ; Humans ; Industrialized nations ; Marketing ; National Health Programs - organization &amp; administration ; Outcome Assessment (Health Care) ; Patients ; Pharmaceutical industry ; Prescription drugs ; Rate Setting and Review ; Statistical analysis ; Studies ; Subsidies</subject><ispartof>Health Affairs, 2001-05, Vol.20 (3), p.104-114</ispartof><rights>Copyright Project Hope May/Jun 2001</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03</citedby><cites>FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/204640319/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$H</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/204640319?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>315,786,790,11715,12874,21415,21422,27899,27957,27958,33258,33646,33647,34020,34021,36095,36096,43768,43983,44398,74578,74825,75252</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/11585158$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Birkett, Donald J</creatorcontrib><creatorcontrib>Mitchell, Andrew S</creatorcontrib><creatorcontrib>McManus, Peter</creatorcontrib><title>A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia</title><title>Health Affairs</title><addtitle>Health Aff (Millwood)</addtitle><description>The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.</description><subject>Australia</subject><subject>Committees</subject><subject>Cost analysis</subject><subject>Cost control</subject><subject>Cost Sharing</subject><subject>Cost-Benefit Analysis</subject><subject>Decision making</subject><subject>Drug Approval</subject><subject>Drug Costs</subject><subject>Drug dosages</subject><subject>Drug Industry - organization &amp; administration</subject><subject>Evidence-Based Medicine</subject><subject>Financing, Government</subject><subject>Formularies as Topic</subject><subject>Government subsidies</subject><subject>Health Services Accessibility - organization &amp; administration</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Industrialized nations</subject><subject>Marketing</subject><subject>National Health Programs - organization &amp; administration</subject><subject>Outcome Assessment (Health Care)</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Prescription drugs</subject><subject>Rate Setting and Review</subject><subject>Statistical analysis</subject><subject>Studies</subject><subject>Subsidies</subject><issn>0278-2715</issn><issn>1544-5208</issn><issn>2694-233X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2001</creationdate><recordtype>article</recordtype><sourceid>7TQ</sourceid><sourceid>8BJ</sourceid><sourceid>ALSLI</sourceid><sourceid>DPSOV</sourceid><sourceid>M0C</sourceid><sourceid>M2R</sourceid><recordid>eNpdkM1r3DAUxEVpaTZJ7zkV0UMhB2_f04dlH802aQKBFpKehSxLawWvvZXshvz3VdklgRweA4_fDMMQcoGwRq7Ut36Ye-P9msGarxHEO7JCKUQhGVTvyQqYqgqmUJ6Q05QeAUqGUH8kJ4iykvlW5LqhmynNxZX3zs7hrxtdSrTZ7-NkbE8fJvo9Llt6v7QpdM-0GTv6KwYbxi29HWmzpDmaIZhz8sGbIblPRz0jv6-vHjY3xd3PH7eb5q6wgtVzIRg3rHW-rsGZ0rYcHdRVBZIbiR6wQ9u5urTghFJKVNBZ8BaZKD2XbQv8jHw95OZ-fxaXZr0LybphMKOblqQVMlRlJTP45Q34OC1xzN00A1EK4FhnCA6QjVNK0Xm9j2Fn4rNG0P8H1seBs0fz_BTZ8vmYu7Q7170ajotm4PIA9GHbP4XodNqZYcg4ajuNsxvnl7B_L6eExA</recordid><startdate>20010501</startdate><enddate>20010501</enddate><creator>Birkett, Donald J</creator><creator>Mitchell, Andrew S</creator><creator>McManus, Peter</creator><general>Health Affairs</general><general>The People to People Health Foundation, Inc., Project HOPE</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>0U~</scope><scope>1-H</scope><scope>3V.</scope><scope>7RV</scope><scope>7T2</scope><scope>7TQ</scope><scope>7WY</scope><scope>7WZ</scope><scope>7X7</scope><scope>7XB</scope><scope>87Z</scope><scope>88C</scope><scope>88E</scope><scope>88J</scope><scope>8AO</scope><scope>8BJ</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8FL</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>AN0</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BEC</scope><scope>BENPR</scope><scope>BEZIV</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DHY</scope><scope>DON</scope><scope>DPSOV</scope><scope>DWQXO</scope><scope>FQK</scope><scope>FRNLG</scope><scope>FYUFA</scope><scope>F~G</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>HCIFZ</scope><scope>JBE</scope><scope>K60</scope><scope>K6~</scope><scope>K9.</scope><scope>KB0</scope><scope>KC-</scope><scope>L.-</scope><scope>L.0</scope><scope>M0C</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2L</scope><scope>M2O</scope><scope>M2R</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PATMY</scope><scope>PQBIZ</scope><scope>PQBZA</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PYCSY</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20010501</creationdate><title>A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia</title><author>Birkett, Donald J ; Mitchell, Andrew S ; McManus, Peter</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2001</creationdate><topic>Australia</topic><topic>Committees</topic><topic>Cost analysis</topic><topic>Cost control</topic><topic>Cost Sharing</topic><topic>Cost-Benefit Analysis</topic><topic>Decision making</topic><topic>Drug Approval</topic><topic>Drug Costs</topic><topic>Drug dosages</topic><topic>Drug Industry - organization &amp; administration</topic><topic>Evidence-Based Medicine</topic><topic>Financing, Government</topic><topic>Formularies as Topic</topic><topic>Government subsidies</topic><topic>Health Services Accessibility - organization &amp; administration</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Industrialized nations</topic><topic>Marketing</topic><topic>National Health Programs - organization &amp; administration</topic><topic>Outcome Assessment (Health Care)</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Prescription drugs</topic><topic>Rate Setting and Review</topic><topic>Statistical analysis</topic><topic>Studies</topic><topic>Subsidies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Birkett, Donald J</creatorcontrib><creatorcontrib>Mitchell, Andrew S</creatorcontrib><creatorcontrib>McManus, Peter</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection【Remote access available】</collection><collection>Global News &amp; ABI/Inform Professional</collection><collection>Trade PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing &amp; Allied Health Database</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>PAIS Index</collection><collection>ABI-INFORM Complete</collection><collection>ABI/INFORM Global (PDF only)</collection><collection>Health &amp; Medical Complete (ProQuest Database)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Social Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>International Bibliography of the Social Sciences (IBSS)</collection><collection>Public Health Database (Proquest)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ABI/INFORM Collection (Alumni Edition)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Social Science Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>British Nursing Database</collection><collection>ProQuest Agriculture &amp; Environmental Science Database</collection><collection>ProQuest Central Essentials</collection><collection>eLibrary</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Business Premium Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>PAIS International</collection><collection>PAIS International (Ovid)</collection><collection>Politics Collection</collection><collection>ProQuest Central Korea</collection><collection>International Bibliography of the Social Sciences</collection><collection>Business Premium Collection (Alumni)</collection><collection>Health Research Premium Collection</collection><collection>ABI/INFORM Global (Corporate)</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>International Bibliography of the Social Sciences</collection><collection>ProQuest Business Collection (Alumni Edition)</collection><collection>ProQuest Business Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>ProQuest Politics Collection</collection><collection>ABI/INFORM Professional Advanced</collection><collection>ABI/INFORM Professional Standard</collection><collection>ABI/INFORM Collection</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>Medical Database</collection><collection>Political Science Database (Proquest)</collection><collection>ProQuest research library</collection><collection>Social Science Database (ProQuest)</collection><collection>Research Library (Corporate)</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>Environmental Science Database</collection><collection>ProQuest One Business</collection><collection>ProQuest One Business (Alumni)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Environmental Science Collection</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Health Affairs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Birkett, Donald J</au><au>Mitchell, Andrew S</au><au>McManus, Peter</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia</atitle><jtitle>Health Affairs</jtitle><addtitle>Health Aff (Millwood)</addtitle><date>2001-05-01</date><risdate>2001</risdate><volume>20</volume><issue>3</issue><spage>104</spage><epage>114</epage><pages>104-114</pages><issn>0278-2715</issn><eissn>1544-5208</eissn><eissn>2694-233X</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>The Australian government offers its citizens subsidies on a select list of pharmaceuticals. For a drug to qualify for inclusion on this list, its manufacturer must demonstrate that the drug is both clinically effective and cost-effective. In part, this measure, along with others, was introduced to improve clinical and economic outcomes. Although this evidence-based system has provided transparency and consistency in decision making about which drugs will be covered, it may not have contained the rate of increase in drug costs.</abstract><cop>United States</cop><pub>Health Affairs</pub><pmid>11585158</pmid><doi>10.1377/hlthaff.20.3.104</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0278-2715
ispartof Health Affairs, 2001-05, Vol.20 (3), p.104-114
issn 0278-2715
1544-5208
2694-233X
language eng
recordid cdi_proquest_miscellaneous_71217685
source International Bibliography of the Social Sciences (IBSS); ABI/INFORM Collection; Politics Collection; Social Science Premium Collection (Proquest) (PQ_SDU_P3); PAIS Index
subjects Australia
Committees
Cost analysis
Cost control
Cost Sharing
Cost-Benefit Analysis
Decision making
Drug Approval
Drug Costs
Drug dosages
Drug Industry - organization & administration
Evidence-Based Medicine
Financing, Government
Formularies as Topic
Government subsidies
Health Services Accessibility - organization & administration
Hospitals
Humans
Industrialized nations
Marketing
National Health Programs - organization & administration
Outcome Assessment (Health Care)
Patients
Pharmaceutical industry
Prescription drugs
Rate Setting and Review
Statistical analysis
Studies
Subsidies
title A Cost-Effectiveness Approach To Drug Subsidy And Pricing In Australia
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-23T05%3A29%3A33IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20Cost-Effectiveness%20Approach%20To%20Drug%20Subsidy%20And%20Pricing%20In%20Australia&rft.jtitle=Health%20Affairs&rft.au=Birkett,%20Donald%20J&rft.date=2001-05-01&rft.volume=20&rft.issue=3&rft.spage=104&rft.epage=114&rft.pages=104-114&rft.issn=0278-2715&rft.eissn=1544-5208&rft_id=info:doi/10.1377/hlthaff.20.3.104&rft_dat=%3Cproquest_cross%3E71217685%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c429t-423a2bef990ea6cb31e0988053a51f01d1cde96c0e4777480dc0fc1246f35bb03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=204640319&rft_id=info:pmid/11585158&rfr_iscdi=true